Moleculin Stock Alpha and Beta Analysis

MBRX
 Stock
  

USD 1.73  0.03  1.76%   

This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Moleculin Biotech CS. It also helps investors analyze the systematic and unsystematic risks associated with investing in Moleculin Biotech over a specified time horizon. Remember, high Moleculin Biotech's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation.
Additionally, see Moleculin Biotech Backtesting, Moleculin Biotech Valuation, Moleculin Biotech Correlation, Moleculin Biotech Hype Analysis, Moleculin Biotech Volatility, Moleculin Biotech History and analyze Moleculin Biotech Performance.
  
Please note that although Moleculin Biotech alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., DOW index.) So in this particular case, Moleculin Biotech did 0.15  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Moleculin Biotech CS stock's relative risk over its benchmark. Moleculin Biotech has a beta of 1.09  . Let's try to break down what Moleculin's beta means in this case. Moleculin Biotech returns are very sensitive to returns on the market. As the market goes up or down, Moleculin Biotech is expected to follow.
Moleculin Biotech Book Value per Share is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Book Value per Share of 2.94 in 2021. Enterprise Value over EBIT is likely to rise to 1.08 in 2022, whereas Tangible Assets Book Value per Share are likely to drop 2.63 in 2022.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.

Moleculin Biotech Quarterly Book Value per Share

2.543

Moleculin Biotech Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Moleculin Biotech market risk premium is the additional return an investor will receive from holding Moleculin Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Moleculin Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Moleculin Biotech's performance over market.
α0.15   β1.09
90 days against DJI

Moleculin Biotech expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Moleculin Biotech's Buy-and-hold return. Our buy-and-hold chart shows how Moleculin Biotech performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Moleculin Biotech Market Price Analysis

Market price analysis indicators help investors to evaluate how Moleculin Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Moleculin Biotech shares will generate the highest return on investment. By understating and applying Moleculin Biotech stock market price indicators, traders can identify Moleculin Biotech position entry and exit signals to maximize returns.

Moleculin Biotech Return and Market Media

The median price of Moleculin Biotech for the period between Tue, May 10, 2022 and Mon, Aug 8, 2022 is 1.5 with a coefficient of variation of 11.32. The daily time series for the period is distributed with a sample standard deviation of 0.17, arithmetic mean of 1.52, and mean deviation of 0.14. The Stock received some media coverage during the period.
 Price Growth (%)  
       Timeline  
1
EPS Reported05/11/2022
2
Financial Statements05/12/2022
3
Financial Statements05/20/2022
4
Financial Statements05/26/2022
5
Filing05/31/2022
6
Financial Statements06/09/2022
7
Financial Statements06/16/2022
8
Exercise or conversion by Foster Jonathan P of 12500 shares ...06/21/2022
9
Acquisition by Yan Joy of 15000 shares of Moleculin Biotech ...06/22/2022
10
Exercise or conversion by Klemp Walter V of 14717 shares of ...07/06/2022
11
Financial Statements07/08/2022
12
Exercise or conversion by Klemp Walter V of 13205 shares of ...07/13/2022
13
Exercise or conversion by Klemp Walter V of 14717 shares of ...07/15/2022
14
Financial Statements07/28/2022

About Moleculin Biotech Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all equity instruments such as Ford or other stocks, funds, and ETFs. Alpha measures the amount that position in Moleculin Biotech has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Moleculin Biotech Upcoming Company Events

As portrayed in its financial statements, the presentation of Moleculin Biotech's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moleculin Biotech's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Moleculin Biotech's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Moleculin Biotech. Please utilize our Beneish M Score to check the likelihood of Moleculin Biotech's management manipulating its earnings.
Upcoming Quarterly Report23rd of March 2022
Next Financial Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Build Portfolio with Moleculin Biotech

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moleculin Biotech Backtesting, Moleculin Biotech Valuation, Moleculin Biotech Correlation, Moleculin Biotech Hype Analysis, Moleculin Biotech Volatility, Moleculin Biotech History and analyze Moleculin Biotech Performance. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Moleculin Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Moleculin Biotech technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Moleculin Biotech trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...